Ariceta G, Dixon BP, Kim SH, Kapur G, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment. Kidney Int 2021;100:225-237.
PMID: 33307104